Basic and Translational Cancer Research

The laboratories of Gerald Bronfman Department of Oncology faculty members who conduct basic and translational research in cancer are located at McGill (Rosalind and Morris Goodman Cancer Research Centre) and its affiliated hospitals (Jewish General Hospital, McGill University Health Centre). Research interests are extensive in scope and cover various types of cancers including breast, prostate, colorectal, ovarian, neurological and pediatric cancers. In addition to research, faculty members are also involved in the teaching and training of the next generation of cancer researchers. 

                         Circle with terms related to cancer research

Rosalind and Morris Goodman Cancer Research Centre

Three researchers working in laboratory
Research at the Rosalind & Morris Goodman Cancer Research Centre (GCRC) focuses on the biochemical, cellular and molecular mechanisms involved in tumourigenesis. A wide range of areas are under investigation, including signal transduction, differentiation, cell proliferation and apoptosis. Many of the cancer researchers located at the hospital-based laboratories are associate members of the GCRC.

GCRC Director: morag.park [at] (Dr. Morag Park)
(514) 398-5749

GCRC General Information: (514) 398-3535

Jewish General Hospital (Lady Davis Institute/Segal Cancer Centre)

Two researchers analyzing data
At the Jewish General Hospital basic and translational cancer research is conducted at the Lady Davis Institute/Segal Cancer Centre (LDI/SCC). Research areas include cancer progression, cancer genomics, targeted new therapies, novel molecular targets, cell and gene therapy in cancer, cancer prevention and cancer genetics. Research is facilitated by the presence of a number of core facilities including the cell processing centre, flow cytometry facility, clinical proteomics facility, pathology research facility, high performance computing facility, peptide synthesis laboratory, cell imaging facility and the Clinical Research Unit for Phase I and early Phase II clinical trials. Many of the researchers at the Segal Cancer Centre are members of the McGill Centre for Translational Research in Cancer (MCTRC).

MCTRC Director: gerald.batist [at] (Dr. Gerald Batist)
(514) 340-8222 x 5418

Cancer Research Program (CRP) of the Research Institute of the McGill University Health Centre (RI-MUHC)

Researcher using pipette in laboratory
The Cancer Research Program (CRP) is composed of three parts in a new state-of-the-art facility that includes: 1) basic cancer research at the Centre for Translational Biology (CTB), a building connected to the hospital, that houses 120 principle investigators including 26 CRP members; 2) clinical cancer research at the Centre for Innovative Medicine (CIM), which occupies an entire floor of the hospital and includes 12 phase I trial beds; and 3) evaluative cancer research at the Centre for Outcomes Research and Evaluation (CORE), that houses 80 investigators including 20 who study cancer. All three components together constitute the CRP and are located side-by-side at the MUHC Glen Site. Integration of all three groups results in research that is patient centered and incorporates basic, clinical and evaluative science. The activities of the CRP are supported by several Technology Platforms that include: Flow Cytometer and Cell sorting, Cellular Imaging, Tissue Banking, Proteomics and Systems Medicine, Microscopy, Molecular Pathology and Small Animal Imaging. As a result, the program can pursue precision care research especially with the MUHC Cedars Cancer Centre within the same complex. The focus of the CRP is on the mechanisms of etiology (hereditary predisposition), cancer spread (metastasis) and progression of disease. Research areas include the identification of new markers and therapeutic targets, gene therapy, tumour suppressor genes, angiogenesis and radiosensitivity.

CRP Leader: peter.metrakos [at] (Dr. Peter Metrakos)
(514) 843-1600

CRP Associate Leader: patricia.tonin [at] (Dr. Patricia Tonin) 
(514) 934-1934 x 44069   


Back to top